Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
39
ZLAB Quote, Financials, Valuation and Earnings
Last price:
$18.18
Seasonality move
:
3.29%
Day range:
$17.82 - $18.56
52-week range:
$16.82 - $44.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.39x
P/B ratio:
2.64x
Volume:
1M
Avg. volume:
903.8K
1-year change:
-28.5%
Market cap:
$2B
Revenue:
$399.2M
EPS (TTM):
-$1.95
Analysts' Opinion
-
Consensus RatingZai Lab Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $49.17, Zai Lab Ltd. has an estimated upside of 171.81% from its current price of $18.09.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.50 representing 100% downside risk from its current price of $18.09.
Fair Value
-
According to the consensus of 9 analysts, Zai Lab Ltd. has 171.81% upside to fair value with a price target of $49.17 per share.
ZLAB vs. S&P 500
-
Over the past 5 trading days, Zai Lab Ltd. has underperformed the S&P 500 by -2.12% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Zai Lab Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zai Lab Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Zai Lab Ltd. reported revenues of $116.2M.
Earnings Growth
-
Zai Lab Ltd. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Zai Lab Ltd. reported earnings per share of -$0.33.
Enterprise value:
1.4B
EV / Invested capital:
--
Price / LTM sales:
4.39x
EV / EBIT:
--
EV / Revenue:
3.18x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.42x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$270.9M
Return On Assets:
-18.24%
Net Income Margin (TTM):
-46.79%
Return On Equity:
-26.7%
Return On Invested Capital:
-21.74%
Operating Margin:
-42.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $263.5M | $355.7M | $441.8M | $102.3M | $116.2M | |
| Gross Profit | $172M | $224.7M | $270.9M | $65.3M | $69.3M | |
| Operating Income | -$349.9M | -$338.2M | -$227.9M | -$67.9M | -$48.9M | |
| EBITDA | -$332M | -$318.7M | -$204.1M | -$63M | -$43.1M | |
| Diluted EPS | -$3.12 | -$2.78 | -$1.95 | -$0.42 | -$0.33 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.6B | $1.2B | $959.7M | $860.5M | $1B | |
| Total Assets | $1.7B | $1.3B | $1B | $985.3M | $1.2B | |
| Current Liabilities | $112M | $155.5M | $124.9M | $286.3M | $359.8M | |
| Total Liabilities | $140.1M | $192.6M | $162.7M | $317.7M | $399M | |
| Total Equity | $1.6B | $1.1B | $881M | $667.7M | $759.9M | |
| Total Debt | $10.7M | $13.9M | $9.8M | $6.1M | $10.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$292.6M | -$174.7M | -$189.2M | -$26.8M | -$40.4M | |
| Cash From Investing | -$29.6M | -$13M | -$28M | -$29.9M | -$4.2M | |
| Cash From Financing | -$7M | $113.2M | $319.2M | $42.2M | $29.1M | |
| Free Cash Flow | -$304.6M | -$219.3M | -$219.1M | -$56.7M | -$44.5M | |
ZLAB
Sector
Market Cap
$2B
$28.1M
Price % of 52-Week High
40.8%
50.9%
Dividend Yield
0%
0%
Shareholder Yield
-6.88%
-1.55%
1-Year Price Total Return
-28.5%
-19.36%
Beta (5-Year)
0.835
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$17.86
200-day SMA
Sell
Level
$30.31
Bollinger Bands (100)
Sell
Level
20.14 - 32.9
Chaikin Money Flow
Sell
Level
-22.4M
20-day SMA
Buy
Level
$17.93
Relative Strength Index (RSI14)
Sell
Level
42.68
ADX Line
Sell
Level
33.77
Williams %R
Neutral
Level
-42.0091
50-day SMA
Sell
Level
$20.70
MACD (12, 26)
Sell
Level
-0.87
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Sell
Level
-2.8M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.3257)
Sell
CA Score
(Annual)
Level (-0.383)
Sell
Beneish M-Score
(Annual)
Level (-1.5011)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.4106)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.
Stock Forecast FAQ
In the current month, ZLAB has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ZLAB average analyst price target in the past 3 months is $49.17.
-
Where Will Zai Lab Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zai Lab Ltd. share price will rise to $49.17 per share over the next 12 months.
-
What Do Analysts Say About Zai Lab Ltd.?
Analysts are divided on their view about Zai Lab Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zai Lab Ltd. is a Sell and believe this share price will drop from its current level to $19.50.
-
What Is Zai Lab Ltd.'s Price Target?
The price target for Zai Lab Ltd. over the next 1-year time period is forecast to be $49.17 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ZLAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zai Lab Ltd. is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ZLAB?
You can purchase shares of Zai Lab Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zai Lab Ltd. shares.
-
What Is The Zai Lab Ltd. Share Price Today?
Zai Lab Ltd. was last trading at $18.18 per share. This represents the most recent stock quote for Zai Lab Ltd.. Yesterday, Zai Lab Ltd. closed at $18.09 per share.
-
How To Buy Zai Lab Ltd. Stock Online?
In order to purchase Zai Lab Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ZLAB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ZLAB
Sector
P/E ratio
--
24.09x
PEG ratio
--
-0.01x
P/B ratio
2.64x
1.83x
Price / LTM sales
4.39x
1.59x
Growth Metrics
ZLAB
Sector
Revenue growth
13.67%
4.68%
Earnings growth
23.04%
10.88%
Revenue (5-year growth)
98.4%
6.45%
Earnings forecast
-$0.43
-$0.18
Profitability
ZLAB
Sector
Profitability FY 2024
$251.3M
$3.6M
Return on invested capital
-21.74%
-31.87%
Return on assets
-18.24%
-28.18%
Return on equity
-26.7%
-37.89%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
ZLAB
Sector
Total cash
$817.2M
$26.2M
Short term investments
$330M
$25.7M
Total assets
$1.2B
$76.7M
Long term debt
$10.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
